title: Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.
abstract: We present a case series of seven patients with metastatic renal cell carcinoma treated with bevacizumab (10 mg/kg) in combination with sunitinib 25-50 mg as salvage therapy after disease progression under sunitinib monotherapy. Two patients had a partial response, four had stable disease, and one patient had disease progression. After a median follow-up of 17.2 mo, median progression-free survival and overall survival were 8.5 and 15.1 mo, respectively. Two patients experienced exacerbation of their preexisting hypertension; there were no grade 4 toxicities. The bevacizumab-sunitinib combination in sunitinib-refractory patients seems active and has a tolerable toxicity profile.
authors.affiliation: Department of Oncology, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
authors.forename: Jacques
authors.initials: J
authors.lastname: Medioni
authors.forename: Eugeniu
authors.initials: E
authors.lastname: Banu
authors.forename: Dominique
authors.initials: D
authors.lastname: Helley
authors.forename: Florian
authors.initials: F
authors.lastname: Scotte
authors.forename: Laure
authors.initials: L
authors.lastname: Fournier
authors.forename: Arnaud
authors.initials: A
authors.lastname: Mejean
authors.forename: Antoine
authors.initials: A
authors.lastname: Chedid
authors.forename: Michel
authors.initials: M
authors.lastname: Azizi
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Andrieu
authors.forename: Stéphane
authors.initials: S
authors.lastname: Oudard
mesh_terms: D000855:Anorexia / Q000139:chemically induced; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001247:Asthenia / Q000139:chemically induced; D000068258:Bevacizumab; D001859:Bone Neoplasms / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D003967:Diarrhea / Q000139:chemically induced; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008113:Liver Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D052016:Mucositis / Q000139:chemically induced; D010190:Pancreatic Neoplasms / Q000556:secondary; D011758:Pyrroles / Q000008:administration & dosage*; D016879:Salvage Therapy / Q000379:methods*; D000077210:Sunitinib
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007211:Indoles; D011758:Pyrroles; D000068258:Bevacizumab; D000077210:Sunitinib